Tiziana completes enrollment for Phase 2 trial in progressive MS study

Tiziana Life Sciences CEO Ivor Elrifi joined Steve Darling from Proactive to announce that patient enrollment has been completed in the company’s randomized, double-blind, placebo-controlled Phase 2 clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The company expects topline data from the study in the third quarter of 2026. In addition, findings from the trial are scheduled to be presented at the Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and ECTRIMS meeting in Toronto in October 2026. The trial represents the first Phase 2 placebo-controlled evaluation of intranasal foralumab and marks an important step in the development of what the company describes as a novel anti-CD3 monoclonal antibody platform targeting neurodegenerative and neuroinflammatory diseases. The multicenter study enrolled 48 participants across multiple leading U.S. sites, with patients receivin...